Mrinal Gounder1, Patrick Schöffski2, Robin L Jones3, Mark Agulnik4, Gregory M Cote5, Victor M Villalobos6, Steven Attia7, Rashmi Chugh8, Tom Wei-Wu Chen9, Thierry Jahan10, Elizabeth T Loggers11, Abha Gupta12, Antoine Italiano13, George D Demetri14, Ravin Ratan15, Lara E Davis16, Olivier Mir17, Palma Dileo18, Brian A Van Tine19, Joseph G Pressey20, Trupti Lingaraj21, Anand Rajarethinam21, Laura Sierra22, Shefali Agarwal21, Silvia Stacchiotti23. 1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: gounderm@mskcc.org. 2. Department of General Medical Oncology, and Laboratory of Experimental Oncology, University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium. 3. Royal Marsden Hospital and Institute of Cancer Research, London, UK. 4. Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. 5. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 6. Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA; Janssen Pharmaceuticals, Spring House, PA, USA. 7. Mayo Clinic, Jacksonville, FL, USA. 8. University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. 9. National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. 10. University of California San Francisco, San Francisco, CA, USA. 11. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 12. The Hospital for Sick Children and Princess Margaret Cancer Center, Toronto, ON, Canada. 13. Institut Bergonie and University of Bordeaux, Bordeaux, France. 14. Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA. 15. MD Anderson Cancer Center, Houston, TX, USA. 16. Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. 17. Gustave Roussy Cancer Institute, Paris, France. 18. University College London Hospitals NHS Foundation Trust, London, UK. 19. School of Medicine, Washington University in St Louis, St Louis, MO, USA. 20. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 21. Epizyme, Cambridge, MA, USA. 22. Epizyme, Cambridge, MA, USA; Bristol Myers Squibb, Cambridge, MA, USA. 23. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Abstract
BACKGROUND: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma. METHODS: In this open-label, phase 2 basket study, patients were enrolled from 32 hospitals and clinics in Australia, Belgium, Canada, France, Germany, Italy, Taiwan, the USA, and the UK into seven cohorts of patients with different INI1-negative solid tumours or synovial sarcoma. Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 (the gene that encodes INI1) alterations, or both; and an Eastern Cooperative Oncology Group performance status score of 0-2. Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints were duration of response, disease control rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacodynamic analyses (primary results reported elsewhere). Time to response was also assessed as an exploratory endpoint. Activity and safety were assessed in the modified intention-to-treat population (ie, patients who received one or more doses of tazemetostat). This trial is registered with ClinicalTrials.gov, NCT02601950, and is ongoing. FINDINGS: Between Dec 22, 2015, and July 7, 2017, 62 patients with epithelioid sarcoma were enrolled in the study and deemed eligible for inclusion in this cohort. All 62 patients were included in the modified intention-to-treat analysis. Nine (15% [95% CI 7-26]) of 62 patients had an objective response at data cutoff (Sept 17, 2018). At a median follow-up of 13·8 months (IQR 7·8-19·0), median duration of response was not reached (95% CI 9·2-not estimable). 16 (26% [95% CI 16-39]) patients had disease control at 32 weeks. Median time to response was 3·9 months (IQR 1·9-7·4). Median progression-free survival was 5·5 months (95% CI 3·4-5·9), and median overall survival was 19·0 months (11·0-not estimable). Grade 3 or worse treatment-related adverse events included anaemia (four [6%]) and weight loss (two [3%]). Treatment-related serious adverse events occurred in two patients (one seizure and one haemoptysis). There were no treatment-related deaths. INTERPRETATION:Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma. A phase 1b/3 trial of tazemetostat plus doxorubicin in the front-line setting is currently underway (NCT04204941). FUNDING: Epizyme.
RCT Entities:
BACKGROUND:Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma. METHODS: In this open-label, phase 2 basket study, patients were enrolled from 32 hospitals and clinics in Australia, Belgium, Canada, France, Germany, Italy, Taiwan, the USA, and the UK into seven cohorts of patients with different INI1-negative solid tumours or synovial sarcoma. Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 (the gene that encodes INI1) alterations, or both; and an Eastern Cooperative Oncology Group performance status score of 0-2. Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints were duration of response, disease control rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacodynamic analyses (primary results reported elsewhere). Time to response was also assessed as an exploratory endpoint. Activity and safety were assessed in the modified intention-to-treat population (ie, patients who received one or more doses of tazemetostat). This trial is registered with ClinicalTrials.gov, NCT02601950, and is ongoing. FINDINGS: Between Dec 22, 2015, and July 7, 2017, 62 patients with epithelioid sarcoma were enrolled in the study and deemed eligible for inclusion in this cohort. All 62 patients were included in the modified intention-to-treat analysis. Nine (15% [95% CI 7-26]) of 62 patients had an objective response at data cutoff (Sept 17, 2018). At a median follow-up of 13·8 months (IQR 7·8-19·0), median duration of response was not reached (95% CI 9·2-not estimable). 16 (26% [95% CI 16-39]) patients had disease control at 32 weeks. Median time to response was 3·9 months (IQR 1·9-7·4). Median progression-free survival was 5·5 months (95% CI 3·4-5·9), and median overall survival was 19·0 months (11·0-not estimable). Grade 3 or worse treatment-related adverse events included anaemia (four [6%]) and weight loss (two [3%]). Treatment-related serious adverse events occurred in two patients (one seizure and one haemoptysis). There were no treatment-related deaths. INTERPRETATION:Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma. A phase 1b/3 trial of tazemetostat plus doxorubicin in the front-line setting is currently underway (NCT04204941). FUNDING: Epizyme.
Authors: Paweł Sobczuk; Huber Bątruk; Paulina Wójcik; Krzysztof Iwaniak; Katarzyna Kozak; Piotr Rutkowski Journal: J Cancer Res Clin Oncol Date: 2022-07-01 Impact factor: 4.553
Authors: Nathaniel W Mabe; Min Huang; Guillermo N Dalton; Gabriela Alexe; Daniel A Schaefer; Anna C Geraghty; Amanda L Robichaud; Amy S Conway; Delan Khalid; Marius M Mader; Julia A Belk; Kenneth N Ross; Michal Sheffer; Miles H Linde; Nghi Ly; Winnie Yao; Maria Caterina Rotiroti; Benjamin A H Smith; Marius Wernig; Carolyn R Bertozzi; Michelle Monje; Constantine S Mitsiades; Ravindra Majeti; Ansuman T Satpathy; Kimberly Stegmaier; Robbie G Majzner Journal: Nat Cancer Date: 2022-07-11
Authors: Samuel V Rasmussen; Jia Xiang Jin; Lissett R Bickford; Andrew D Woods; Felix Sahm; Kenneth A Crawford; Kiyo Nagamori; Hiroaki Goto; Keila E Torres; Angelo Sidoni; Erin R Rudzinski; Khin Thway; Robin L Jones; Alessio Ciulli; Hollis Wright; Melvin Lathara; Ganapati Srinivasa; Kavya Kannan; Paul H Huang; Thomas G P Grünewald; Noah E Berlow; Charles Keller Journal: Clin Transl Med Date: 2022-07
Authors: Silvia Stacchiotti; Anna Maria Frezza; Jean-Yves Blay; Elizabeth H Baldini; Sylvie Bonvalot; Judith V M G Bovée; Dario Callegaro; Paolo G Casali; RuRu Chun-Ju Chiang; George D Demetri; Elisabeth G Demicco; Jayesh Desai; Mikael Eriksson; Hans Gelderblom; Suzanne George; Mrinal M Gounder; Alessandro Gronchi; Abha Gupta; Rick L Haas; Andrea Hayes-Jardon; Peter Hohenberger; Kevin B Jones; Robin L Jones; Bernd Kasper; Akira Kawai; David G Kirsch; Eugene S Kleinerman; Axel Le Cesne; Jiwon Lim; María Dolores Chirlaque López; Roberta Maestro; Rafael Marcos-Gragera; Javier Martin Broto; Tomohiro Matsuda; Olivier Mir; Shreyaskumar R Patel; Chandrajit P Raut; Albiruni R A Razak; Damon R Reed; Piotr Rutkowski; Roberta G Sanfilippo; Marta Sbaraglia; Inga-Marie Schaefer; Dirk C Strauss; Kirsten Sundby Hall; William D Tap; David M Thomas; Winette T A van der Graaf; Winan J van Houdt; Otto Visser; Margaret von Mehren; Andrew J Wagner; Breelyn A Wilky; Young-Joo Won; Christopher D M Fletcher; Angelo P Dei Tos; Annalisa Trama Journal: Cancer Date: 2021-04-28 Impact factor: 6.860